title: Icodextrin-induced peritonitis: study of five cases and comparison with bacterial peritonitis.
abstract: BACKGROUND
  An epidemic of aseptic peritonitis related to the presence of peptidoglycan contaminant in some batches of icodextrin solution (Extraneal, Baxter Healthcare Corporation) occurred in Europe in the first six months of 2002.
  
  
  METHODS
  By case-control study we examined the clinical and biologic features of 5 patients with icodextrin-induced peritonitis (group AP) and compared them with 7 patients with bacterial peritonitis (group BP) recruited in our clinical center between January and June 2002.
  
  
  RESULTS
  Diagnosis of icodextrin-induced peritonitis was confirmed in all cases by a positive reintroduction test with contaminated batches of icodextrin. No recurrence was observed on re-exposure to icodextrin free of peptidoglycan. Skin tests were positive with contaminated icodextrin in 2 of 5 patients, while they were negative with icodextrin solution free of peptidoglycan (<0.6 ng/mL). During peritonitis, serum level of C-reactive protein (CRP) was lower in group AP (42.4 +/- 34 mg/L) than in group BP (135 +/- 59 mg/L) (P= 0.01). Leukocyte number in peritoneal dialysis effluent was lower in group AP (284 +/- 101/mm3), with a lower neutrophil/monocyte ratio (N/M = 0.67) than in group BP (1410 +/- 973/mm3; N/M = 4) (P < 0.05). A low number of peritoneal fluid eosinophilia (11 +/- 8%) was detected in group AP.
  
  
  CONCLUSIONS
  Icodextrin-induced peritonitis was associated with a burst of intraperitoneal cytokines. The phenotype of peritoneal neutrophils was different between aseptic and bacterial peritonitis, indicating that inflammatory stimuli that activate neutrophils in both types of peritonitis are clearly distinct. Finally, peritoneal injury measured by weight gain, peritoneal permeability, and CA125 concentration seemed to be less severe during icodextrin-induced peritonitis than during bacterial peritonitis.
authors.affiliation: Department of Nephrology, University Hospital of Reims, France.
authors.forename: Fatouma
authors.initials: F
authors.lastname: Touré
authors.forename: Sylvie
authors.initials: S
authors.lastname: Lavaud
authors.forename: Mehdi
authors.initials: M
authors.lastname: Mohajer
authors.forename: François
authors.initials: F
authors.lastname: Lavaud
authors.forename: Eric
authors.initials: E
authors.lastname: Canivet
authors.forename: Philippe
authors.initials: P
authors.lastname: Nguyen
authors.forename: Jacques
authors.initials: J
authors.lastname: Chanard
authors.forename: Philippe
authors.initials: P
authors.lastname: Rieu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000276:immunology*; D016022:Case-Control Studies; D016207:Cytokines / Q000378:metabolism; D015314:Dialysis Solutions / Q000009:adverse effects*; D005260:Female; D005936:Glucans / Q000009:adverse effects* / Q000276:immunology; D005947:Glucose / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D000077607:Icodextrin; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D018375:Neutrophil Activation; D010457:Peptidoglycan / Q000276:immunology; D010530:Peritoneal Dialysis; D010538:Peritonitis / Q000139:chemically induced* / Q000276:immunology / Q000382:microbiology
chemical_list: D016207:Cytokines; D015314:Dialysis Solutions; D005936:Glucans; D010457:Peptidoglycan; D000077607:Icodextrin; D005947:Glucose